Development of Farnesyl Transferase Inhibitors: A Review

Development of Farnesyl Transferase Inhibitors: A Review N. M. G. M. Appels, J. H. Beijnen, Jan H. M. Schellens Oncologist 2005; 10: 565-578 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the potential mechanisms by which farnesyl transferases inhibit tumor growth. Explain possible mechanisms by which tumor cells may develop resistance to this class of agents. Discuss the scientific requirements for developing targeted cancer treatments that will actually be useful in patients. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Sep. 21, 2005 Most Recent Review: Sep. 21, 2005* Most Recent Update: Sep. 21, 2005 Date Credit Expires: Sep. 21, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.